04/08/2023 1

India’s Foremost Biotech Company

BIOCON LIMITED

Delivering Affordable Innovation

GROUP 6

ARJUN SREENIVASAN- 123RAJU PATOWARY- 166MARU GAURAV- 142LOKESH OSWAL-162VINOD KUMAR-179POOJA GANHAR-130

04/08/2023 2

Indian Bio Technology sector is among the five rising biotech industries in the region of Asia-Pacific.

The Indian Bio Tech industry is the biggest producer of vaccine in the world.

There are 325 different companies with the Indian biotech industry.

The total revenue generated annually is around US$ 2 billion.

Overview of Biotechnological Sector

04/08/2023 3

18.50%

26.30%55.20%

GDP- Composition by sector

AgricultureIndustryServices

GDP(PPP)- $4.060 trillionBioTech Sector – 2.2%

04/08/2023 4

75%

9%7%

7%2%

INDIAN BIOTECHNOLOGICAL SECTOR-SEGMENT

BioPharmaBioServicesBioAgriBioIndustrialBioInformatics

The Bio Tech industry in India has the maximum number of companies operating under it.

The growth rate of the sector is around 35 to 40 % annually.

The biotechnology sector comprises of several fields such as bio agriculture, bio pharmaceuticals, bio fuels, etc.

04/08/2023 5

Background

Biocon was found in November 29th 1978

Focused from enzymes manufacturing to development of Biopharmaceuticals

India’s first billion dollar biotech company

1st in India and 20th in world in terms of revenue and market capitalization

Joint venture between Leslie Auchincloss and Kiran Mazumdar

Milestones

1978: Biocon India collaborated with Biocon Chemicals Ltd.1979: Manufactured and exported enzymes to USA and Europe1989: Unilever acquired Biocon Chemicals Ltd.1994: Establishes Syngene1996: Entered Pharmaceuticals and Statins1998: Biocon buys Unilever’s shareholding and became an independent entity2000: Establishes Clingene2001: US FDA approval for manufacture of Lovastatin2003: First company to develop human insulin on a Pichia expression system2006: Launches India’s first anticancer drug, BioMab 2008:Biocon is ranked among the top 20 global biotechnology companies (Med Ad News).2010: Biocon and Pfizer  announce strategic global agreement

04/08/2023 7

BIOCON AND ITS SUBSIDIARIES

04/08/2023 8

NEWSNEWS

04/08/2023 9

04/08/2023 10

CEO- Mrs. Kiran Mazumdar -Shaw

1953- Born in India

1973- B.sc in Zoology

1975- Master in Melting & brewing from Ballarat College , Melbourne University

1978- Started from her garage with initial capital of Rs. 10000.

04/08/2023 11

04/08/2023 12

Contribution of each of the components of Biocon’s income expressed as a percentage of

Biocon’s total

Biopharmaceuticals85%

Enzymes5%

Research Services5%

Others6%

Biopharmaceuticals EnzymesResearch Services Others

04/08/2023 13

THE DEALS THAT ARE CHANGING THE GAME

04/08/2023 14

Products

04/08/2023 15

INSUGEN® 30/70 40 IUINSUGEN® 50/50 40 IUINSUGEN® N 40 IUINSUGEN® R 40 IUActive Ingredient: Each ml containsHuman Insulin (rDNA origin).Indication: In Diabetes, useful when oralagents fail to control blood glucose levels

STATIX® - EZActive Ingredient: Atorvastatin10 mg tablets.Indication: Controls extremelyhigh levels of cholesterol

04/08/2023 16

FINANCE

04/08/2023 17

Overview of Financial Strengths

Biocon Limited serves partners and customers in over 50 countries

It ranks first in Asia’s Biotech Industry in terms of Market Capitalization.

Biocon Limited had its Initial Public Offering (IPO) in 2004

Second Indian company to cross a market capitalization of 1 Billion US dollars on the first day of listing.

04/08/2023 18

Biocon’s Finances stem from major areas:-

Biopharmaceutical Products- such as branded and generic drugs, APIs

Customer Research Services- in the areas of preclinical and clinical research

Manufacturing and Marketing

FINANCIAL YEAR ENDING MARCH

Please click here to see Profit and Loss Report from FY2007 to FY2011

FY 2007 FY 2008 FY 2009 FY 2010 FY 20110

500

1000

1500

2000

2500

3000

9901090

1673

2405

2814

773 852

1413

2053

2367

200 225 240 303 375

Sales, Expenditure and Profit from FY2007 to FY2011

SALES EXPENDITURE PROFITFigure in Rs. (Crores)

04/08/2023 21

52 Week High, Low Share Price

Last Five Years High, Low Share Price

22

Competitors

Wednesday, September 21, 2011

04/08/2023 23

Competitors List

04/08/2023 24

Sun Pharmaceuticals Industries Ltd. (Oncology)

o Now at a stage of rapid growth across geographies spanning Russia, China, South East Asia, Africa and Latin America.

o No. 1 in India in speciality therapy areas like psychiatry, neurology, cardiology among the top 3 companies in a total of 7 therapy areas. Wockhardt Limited

o A recent addition to the company’s product basket is Wosulin Pen and Catridge, an automatic insulin delivery device- for the convenience of diabetic patients.

04/08/2023 25

SWOT Analysis

StrengthsWeaknesse

s

Low Price Insugen price of $2.5 per 10ml Debt free and cash rich status Rich and expanding new drug pipeline Biocon’s R&D expertise

Statin dependent Limited clientele -Revenue profile is highly concentrated.

04/08/2023 26

Opportunities

Threats

Market potential --Statins market likely to grow at a rate of 18% in the next year

India has the most quantity and diverse type of diabetes.

Manufacturing Capabilities

Expiration of patents worldwide

Regulatory risk

Competitive threat

Raw materials and fuel costs are linked to global commodity prices.

Dollar depreciation---- rising personnel costs and increasing operational overheads on account of oil and power

04/08/2023 27

It started a corporate social responsibility wing – the Biocon Foundation – in 2004 through which it works in the areas of health, education and infrastructure, especially in rural areas.

HealthThrough the Arogya Raksha Yogana (ARY) clinics, Biocon helps meet the primary, tertiary and secondary healthcare needs of various communities.

EducationIn a scheme aimed at popularising mathematics among Karnataka’s rural children, Biocon has started the Chinnara Ganitha program.

InfrastructureThe Biocon Foundation has helped build infrastructure in several communities by constructing school buildings, crèches, sanitary facilities, and water supply connections.

Flood ReliefWhen floods devastated North Karnataka in September/October 2009, the Biocon Foundation dispatched doctors and nurses and helped treat more than 5,000 patients. The Foundation is also helping rebuild 1,000 homes destroyed in the floods in three affected villages of Bagalkot district.

Corporate Social Responsibility

04/08/2023 28

Awards and Achievements1985- National Award for Best Small Industry, Government of India2000- Technology Pioneer Recognition, World Economic Forum2004-India's first and No. 1 biotech company with a global ranking of 16* (Source: Biospectrum July 2004)2006-Best IT User Award in the Pharmaceutical Sector, NASSCOM2009-Biocon among Top 20 Indian companies in Forbes ‘Best Under A Billion’ list.2009-Biocon bags IDMA "Best Patent of the year" award2009-Biocon wins prestigious BioSingapore Asia Pacific Biotechnology Award for Best Listed Company.2010-Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio

04/08/2023 29